Literature DB >> 19544202

First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction.

Irene Cetin1, Veronica Cozzi, Aris T Papageorghiou, Virginia Maina, Alessandro Montanelli, Cecilia Garlanda, Basky Thilaganathan.   

Abstract

Pentraxin 3 (PTX3) and C-reactive protein (CRP) levels were measured in the first trimester of pregnancy in women who subsequently developed preeclampsia (PE, n=16) and fetal growth restriction (FGR, n=12) requiring iatrogenic delivery before 37 weeks, and those who had uncomplicated pregnancies delivering at term (n=60). Mean PTX3 levels were significantly higher in women who subsequently developed PE (7.31 ng/ml, SD = 4.12) when compared to those with normal pregnancy outcome (4.92 ng/ml, SD = 1.94, p=0.0046). There were no significant differences between PTX3 levels in women with FGR (4.82 ng/ml, SD = 2.35) compared to normal pregnancy outcome (p=0.88). The median CRP levels did not vary significantly between the three groups (p=0.26). PTX3 levels in women who subsequently develop PE are already elevated in the first trimester, but not in those that develop FGR. This supports the hypothesis of an excessive maternal inflammatory response to pregnancy in the etiology of PE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544202     DOI: 10.1080/00016340902971441

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  8 in total

1.  Neurokinin 3 receptor and phosphocholine transferase: missing factors for pathogenesis of C-reactive protein in preeclampsia.

Authors:  Nicholas F Parchim; Wei Wang; Takayuki Iriyama; Olaide A Ashimi; Athar H Siddiqui; Sean Blackwell; Baha Sibai; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2014-12-01       Impact factor: 10.190

2.  The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum.

Authors:  Ping Zhou; Xin Luo; Hong-Bo Qi; Wen-Jun Zong; Hua Zhang; Dan-Dan Liu; Qing-Shu Li
Journal:  Inflamm Res       Date:  2012-06-20       Impact factor: 4.575

Review 3.  Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  World J Nephrol       Date:  2014-11-06

4.  Pentraxin 3 values during normal pregnancy.

Authors:  Anders Larsson; Maria Palm; Johanna Helmersson; Ove Axelsson
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

5.  Pentraxin 3 in maternal circulation: an association with preterm labor and preterm PROM, but not with intra-amniotic infection/inflammation.

Authors:  Laura Cruciani; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Shali Mazaki-Tovi; Zhong Dong; Sun Kwon Kim; Giovanna Ogge; Lami Yeo; Pooja Mittal; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-10

Review 6.  Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?

Authors:  Sinuhe Hahn; Olav Lapaire; Nandor Gabor Than
Journal:  Expert Rev Mol Diagn       Date:  2015-03-16       Impact factor: 5.225

Review 7.  Pentraxin 3 in Cardiovascular Disease.

Authors:  Giuseppe Ristagno; Francesca Fumagalli; Barbara Bottazzi; Alberto Mantovani; Davide Olivari; Deborah Novelli; Roberto Latini
Journal:  Front Immunol       Date:  2019-04-17       Impact factor: 7.561

8.  Novel Early Pregnancy Multimarker Screening Test for Preeclampsia Risk Prediction.

Authors:  Kaspar Ratnik; Kristiina Rull; Oliver Aasmets; Triin Kikas; Ele Hanson; Kalle Kisand; Krista Fischer; Maris Laan
Journal:  Front Cardiovasc Med       Date:  2022-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.